Base de dados : MEDLINE
Pesquisa : C04.588.945.418.365 [Categoria DeCS]
Referências encontradas : 2274 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 228 ir para página                         

  1 / 2274 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424983
[Au] Autor:Gómez-Pue D; Ibarrola-BuenAbad E; Lara-Núñez D; Vázquez-Alvarado AP; Pérez-Quintanilla M
[Ti] Título:[Salpingectomy in ovarian cancer prevention: Evidence behind the hypothesis and surgical implications].
[Ti] Título:Salpingectomía como opción de reducción de riesgo de cáncer de ovario..
[So] Source:Ginecol Obstet Mex;84(9):614-9, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Background: Over the last decade, evidence suggests the fallopian tubes are the origin of most of the high grade ovarian serous carcinomas. This type of carcinoma represents at least 50% of all the cases of epithelial ovarian cancer. Salpingectomy may lower the risk of high grade serous carcinoma. Removing the two fallopian tubes should be considered a strategy for risk reduction in patients who decide tubal sterilization or in patients with hysterectomy for benign disease. There are ongoing protocols that evaluate the ovarian hormonal production impact after prophilactic salpingectomy. In patients with BRCA1 and BRCA2 mutations, salpingo-oophorectomy is recommended usually between 35 to 40 years of age for BRCA 1 and between 40 and 45 years of age for BRCA 2. The oopherectomy done whithin these decades has the consequences and side effects of premature menopause, some physicians have suggested doing a two step procedure: perform a salpingectomy as soon as the patient has decided to have permanent birth control, and doing the ophoorectomy at the onset of menopause. The oncological safety of this approach is still under evaluation and is not recommended outside a protocol.
[Mh] Termos MeSH primário: Neoplasias das Tubas Uterinas/prevenção & controle
Neoplasias Ovarianas/prevenção & controle
Salpingectomia/métodos
[Mh] Termos MeSH secundário: Adulto
Proteína BRCA1/genética
Proteína BRCA2/genética
Tubas Uterinas/cirurgia
Feminino
Seres Humanos
Neoplasias Ovarianas/genética
Ovariectomia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (BRCA1 Protein); 0 (BRCA1 protein, human); 0 (BRCA2 Protein); 0 (BRCA2 protein, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  2 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277804
[Au] Autor:Bacalbasa N; Balescu I; Brasoveanu V; Anca AF
[Ad] Endereço:"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
[Ti] Título:Debulking Surgery for Pelvic Recurrence After Surgically-treated Tubal Gestational Choriocarcinoma - A Case Report and Literature Review.
[So] Source:Anticancer Res;38(1):423-426, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Gestational choriocarcinomas are very rare malignancies, with only few cases being reported so far. Moreover, the presence of pelvic recurrences after surgically-treated gestational choriocarcinomas is even scarcer situations. We present the case of a 19-year-old patient who was initially submitted to surgery with preoperative diagnosis of ectopic pregnancy. At that moment a left salpingectomy was performed, and the histopathological studies revealed the presence of a left tubal gestational choriocarcinoma. The patient was submitted to adjuvant chemotherapy with methotrexate and dactinomycin. However, six months later she was diagnosed with a pelvic recurrence so she was resubmitted to surgery, debulking to no residual disease being successfully performed. The histopathological studies confirmed the presence of a recurrent tumor with gestational choriocarcinoma structure.
[Mh] Termos MeSH primário: Coriocarcinoma/cirurgia
Procedimentos Cirúrgicos de Citorredução/métodos
Neoplasias das Tubas Uterinas/cirurgia
Doença Trofoblástica Gestacional/cirurgia
Complicações Neoplásicas na Gravidez/cirurgia
Salpingectomia
[Mh] Termos MeSH secundário: Adulto
Antibióticos Antineoplásicos/uso terapêutico
Antimetabólitos Antineoplásicos/uso terapêutico
Coriocarcinoma/tratamento farmacológico
Dactinomicina/uso terapêutico
Feminino
Seres Humanos
Metotrexato/uso terapêutico
Recidiva Local de Neoplasia
Gravidez
Gravidez Ectópica/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 0 (Antimetabolites, Antineoplastic); 1CC1JFE158 (Dactinomycin); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  3 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29060967
[Au] Autor:Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
[Ad] Endereço:Laboratory of Early Prevention and Treatment for Regional High Frequence Tumor Ministry of Education Key Laboratory, Affiliated Tumor Hospital, Guangxi Medical University, Nanning 530021, China.
[Ti] Título:[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;52(10):687-696, 2017 Oct 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To explore the origin of ovarian high grade serous carcinoma (HGSC) through analysing the expression and significance of PAX8, PAX2, p53 and RAS in the ovary and fallopian tube of different types and grades of serous carcinoma. A total of 44 cases tissue samples of ovarian tumor including 34 malignant ovarian tumor and 10 normal normal tissue (as control group) were collected from the admitted patients in Affiliated Tumor Hospital of Guangxi Medical University from January 2015 to January 2016. Fallopian tube tissues were segmented in accordance with the fimbria, ampulla, isthmus and the corresponding ovarian tissues were by the side. There were 34 cases of patients with ovarian cancer including 29 cases of epithelial ovarian cancer (27 serous carcinoma, 1 mucinous carcinoma,1 endometrioid adenocarcinoma) and 5 non-epithelial ovarian cancer (sex cord-interstitial tumor). Among 27 cases of patients with ovarian serous cancer, there were 23 HGSC and 4 low-grade ovarian serous cancer (LGSC). One hundred fifty-three cases of samples were diagnosed as ovarian serous cancer by Shandong University Affiliated Qilu Hospital from 2005 to 2013 and these samples were made tissue microarray. (1) To analyze the expression and differences of PAX8, PAX2, p53 and RAS in the above tissues and tissue microarray from ovarian and tubal of HGSC and control women by immunohistochemistry methods. (2) To compare the expression levels of PAX8, PAX2, p53 and RAS in ovarian and fallopian tubes of ovarian cancer patients with different pathological types. (3) To analyze the correlations of tubal and ovarian tissue in PAX8, PAX2, p53 and RAS expression of HGSC. (4) To analyze the factors of the prognosis of ovarian serous cancer in tissue microarray by single factor analysis method. (1) PAX8, PAX2, p53 and RAS expression was negative in normal ovarian epithelium of control group, but the expression of PAX8, PAX2, p53 and RAS were strongly positive brown in secrete cells of normal fallopian tube epithelium. (2) p53 and RAS expression of fallopian tube epithelium in the epithelial ovarian cancer group were significantly higher than those in the non-epithelial ovarian cancer groups ( 0.05), but the expression of PAX8 and PAX2 in fallopian tube and the expression of PAX8, PAX2, p53 and RAS in ovarian tissue was not statistically significant in the groups ( 0.05). PAX8, PAX2 and p53 expression of the ovarian in HGSC group were significantly higher than those in LGSC group ( 0.05), while the expression of RAS was lower in the ovarian of the high-grade group ( 0.05), while the expression of PAX8, PAX2, p53 and RAS in fallopian tube was not statistically significant in the groups ( 0.05). (3) There was a significantly positive correlation between fallopian tube and the corresponding ovary of HGSC in PAX8 and PAX2 expression ( 0.422, 0.045; 0.693, 0.000), but not correlation in p53 and RAS expression ( 0.058, 0.793; 0.190, 0.384). (4) Univariate survival analysis showed that the progression free survival time in patients with ovarian serous cancer group was significantly correlated with the protein expression of PAX8, PAX2 and RAS ( 0.05), but there were not correlated with age, surgical staging, cell differentiation, lymph node metastasis and preoperative chemotherapy and p53 protein expression ( 0.05). The total survival time in patients with ovarian serous cancer group was significantly correlated with the protein expression of PAX8 ( 0.05), but there were not correlated with age,surgical staging, cell differentiation, lymph node metastasis and preoperative chemotherapy and the protein expression of PAX2, RAS and p53 ( 0.05). PAX8, PAX2, p53, RAS are of great significance for the study of origin of HGSC. HGSC may be derived from fallopian tube, but further investigation would be necessary to confirm this. PAX8, PAX2, p53, RAS could be expected to be used as predictors of survival prognosis in patients with ovarian serous cancer.
[Mh] Termos MeSH primário: Cistadenocarcinoma Seroso/patologia
Neoplasias das Tubas Uterinas/patologia
Tubas Uterinas/patologia
Proteínas Monoméricas de Ligação ao GTP/metabolismo
Neoplasias Epiteliais e Glandulares/patologia
Neoplasias Ovarianas/patologia
Fator de Transcrição PAX2/metabolismo
Fator de Transcrição PAX8/metabolismo
Proteína Supressora de Tumor p53/metabolismo
[Mh] Termos MeSH secundário: Carcinoma Endometrioide
China
Cistadenocarcinoma Seroso/genética
Cistadenocarcinoma Seroso/metabolismo
Epitélio
Neoplasias das Tubas Uterinas/genética
Neoplasias das Tubas Uterinas/metabolismo
Tubas Uterinas/metabolismo
Feminino
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Imuno-Histoquímica
Proteínas Monoméricas de Ligação ao GTP/genética
Proteínas de Neoplasias/genética
Proteínas de Neoplasias/metabolismo
Neoplasias Epiteliais e Glandulares/genética
Neoplasias Epiteliais e Glandulares/metabolismo
Neoplasias Ovarianas/genética
Neoplasias Ovarianas/metabolismo
Fator de Transcrição PAX2/genética
Fator de Transcrição PAX8/genética
Proteína Supressora de Tumor p53/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neoplasm Proteins); 0 (PAX2 Transcription Factor); 0 (PAX2 protein, human); 0 (PAX8 Transcription Factor); 0 (PAX8 protein, human); 0 (Tumor Suppressor Protein p53); EC 3.6.5.2 (Monomeric GTP-Binding Proteins); EC 3.6.5.2 (REM2 protein, human)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2017.10.008


  4 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28968160
[Au] Autor:Singh R; Cho KR
[Ti] Título:Serous Tubal Intraepithelial Carcinoma or Not? Metastases to Fallopian Tube Mucosa Can Masquerade as In Situ Lesions.
[So] Source:Arch Pathol Lab Med;141(10):1313-1315, 2017 Oct.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: - Nonuterine high-grade serous carcinomas (HGSCs) are believed to arise most often from precursors in the fallopian tube referred to as serous tubal intraepithelial carcinomas (STICs). A designation of tubal origin has been suggested for all cases of nonuterine HGSC if a STIC is identified. OBJECTIVE: - To highlight that many different types of nongynecologic and gynecologic carcinomas, including HGSC, can metastasize to the tubal mucosa and mimic de novo STIC. DATA SOURCES: - A mini-review of several recently published studies that collectively examine STIC-like lesions of the fallopian tube. CONCLUSIONS: - The fallopian tube mucosa can be a site of metastasis from carcinomas arising elsewhere, and pathologists should exercise caution in diagnosing STIC without first considering the possibility of metastasis. Routinely used immunohistochemical stains can often be used to determine if a STIC-like lesion is tubal or nongynecologic in origin. In the context of uterine and nonuterine HGSC, STIC may represent a metastasis rather than the site of origin, particularly when widespread disease is present.
[Mh] Termos MeSH primário: Carcinoma in Situ/patologia
Cistadenocarcinoma Seroso/secundário
Neoplasias das Tubas Uterinas/secundário
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2017-0231-RA


  5 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28906381
[Au] Autor:Takahashi A; Kato K; Matsuura M; Katsuda T; Matoda M; Nomura H; Okamoto S; Kanao H; Kondo E; Omatsu K; Utsugi K; Takeshima N
[Ad] Endereço:Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
[Ti] Título:Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients.
[So] Source:Medicine (Baltimore);96(37):e8006, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To compare secondary cytoreductive surgery (SCS) plus chemotherapy with chemotherapy alone in Japanese patients with recurrent epithelial ovarian, tubal, or peritoneal cancer (ROC).From our institutional database, we identified 112 patients who underwent therapy for ROC between 2005 and 2013. Of the 112 patients, 77 received salvage chemotherapy alone (CT group) and 35 received SCS plus chemotherapy (SCS group). To reduce the impact of treatment selection bias on treatment outcomes, propensity score-matching analysis was used.In the entire cohort, prognostic features were poorer in the CT group than in the SCS group. The platinum-free interval was significantly lower (15.35 months vs 30.77 months), cancer antigen 125 (CA125) level was significantly higher (247.38 IU/mL vs 83.17 IU/mL), and number of solitary recurrence sites was significantly lower in the CT group than in the SCS group. The matched cohort consisted of 29 CT and 29 SCS patients with a median follow-up period of 24 and 58 months, respectively. In the matched cohort, progression-free survival (PFS) was longer in the SCS group than in the CT group (P = .02); however, overall survival did not differ (P = .23).SCS might be associated with improved PFS in ROC patients. SCS is beneficial in appropriately selected ROC patients.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos de Citorredução
Neoplasias das Tubas Uterinas/tratamento farmacológico
Neoplasias das Tubas Uterinas/cirurgia
Recidiva Local de Neoplasia/tratamento farmacológico
Recidiva Local de Neoplasia/cirurgia
Neoplasias Ovarianas/tratamento farmacológico
Neoplasias Ovarianas/cirurgia
Neoplasias Peritoneais/tratamento farmacológico
Neoplasias Peritoneais/cirurgia
[Mh] Termos MeSH secundário: Terapia Combinada
Intervalo Livre de Doença
Neoplasias das Tubas Uterinas/mortalidade
Feminino
Seres Humanos
Meia-Idade
Recidiva Local de Neoplasia/mortalidade
Neoplasias Ovarianas/mortalidade
Neoplasias Peritoneais/mortalidade
Pontuação de Propensão
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008006


  6 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28885412
[Au] Autor:Lippitt MH; Fairbairn MG; Matsuno R; Stone RL; Tanner EJ; Wick EC; Angarita AC; Roche KL; Levinson KL; Bergstrom JE; Sinno AK; Curless MS; Wethington S; Temkin SM; Efron J; Hobson D; Fader AN
[Ad] Endereço:Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, Maryland; the Department of Surgery, Johns Hopkins University, Baltimore, Maryland; Moores Cancer Center, University of California, San Diego, La Jolla, California; the Department of Gynecologic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; and Hospital Epidemiology and Infection Control, Johns Hopkins Hospital, Baltimore, Maryland.
[Ti] Título:Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.
[So] Source:Obstet Gynecol;130(4):756-764, 2017 Oct.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To identify risk factors for surgical site infection and to define rates associated with cytoreductive surgery before and after implementation of an infection prevention bundle. METHODS: We conducted a prospective quality improvement study. Patients who underwent ovarian, fallopian tube, or peritoneal cancer cytoreductive surgery at an academic tertiary care center from April 2014 to April 2016 were prospectively enrolled. Patient demographics, surgical variables, and surgical site infection rates were compared with a historical cohort after introduction of a 5-point infection prevention bundle, including: 1) preoperative and intraoperative skin preparation with 4% chlorhexidine and intraoperative vaginal preparation with 4% chlorhexidine; 2) preoperative use of oral antibiotics and mechanical bowel preparation; 3) appropriate timing of intraoperative antibiotics; 4) adoption of enhanced sterile surgical techniques for colon procedures and incisional closure; and 5) perioperative incision management. RESULTS: During the study period, 219 women underwent surgery: 91 prebundle and 128 treated in the postbundle period. Stage, body mass index, proportion of patients undergoing colon or upper abdominal surgery, and estimated blood loss were not different between the cohorts. Overall, the surgical site infection rate prebundle was 18 (20%); this was reduced to four (3%) postbundle (odds ratio [OR] 0.13, 95% CI 0.037-0.53; P<.001). Patients who underwent a colon resection prebundle had an infection rate of 14 (33%) compared with three (7%) in the postbundle group (OR 0.14, 95% CI 0.037-0.53; P<.001). Additionally, rates of surgical site infection-related hospital readmission were also lower in the postbundle (4/128 [3%]) compared with the prebundle group (12/91 [13%]; P=.005). CONCLUSION: Infection is common after ovarian cancer cytoreductive surgery. Implementation of a 5-point surgical site infection prevention bundle in women undergoing ovarian cancer operations was associated with dramatically decreased infection rates and lower hospital readmission rates.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos de Citorredução/métodos
Neoplasias Ovarianas/cirurgia
Pacotes de Assistência ao Paciente/métodos
Infecção da Ferida Cirúrgica/prevenção & controle
[Mh] Termos MeSH secundário: Abdome/cirurgia
Antibacterianos/administração & dosagem
Anti-Infecciosos Locais/administração & dosagem
Antibioticoprofilaxia/métodos
Antibioticoprofilaxia/normas
Clorexidina/administração & dosagem
Colo/cirurgia
Procedimentos Cirúrgicos de Citorredução/efeitos adversos
Procedimentos Cirúrgicos de Citorredução/normas
Neoplasias das Tubas Uterinas/cirurgia
Feminino
Seres Humanos
Meia-Idade
Razão de Chances
Pacotes de Assistência ao Paciente/normas
Readmissão do Paciente
Neoplasias Peritoneais/cirurgia
Estudos Prospectivos
Melhoria de Qualidade
Infecção da Ferida Cirúrgica/epidemiologia
Infecção da Ferida Cirúrgica/etiologia
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Infective Agents, Local); R4KO0DY52L (Chlorhexidine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002213


  7 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28860006
[Au] Autor:Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, United States. Electronic address: bgoff@uw.edu.
[Ti] Título:Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
[So] Source:Gynecol Oncol;147(2):291-295, 2017 Nov.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess a simple algorithm of CA125, HE4 and Symptom Index to predict ovarian cancer in women with a pelvic mass. METHODS: This was a prospective study of women referred to a gynecologic oncology clinic for surgical evaluation of a pelvic mass. Preoperatively, women completed a SI and had serum markers drawn. Results were correlated with pathology. A triple screen was considered positive if at least 2 of the 3 markers were abnormal (positive SI, CA125≥35U/mL, HE4≥140pmol/L). RESULTS: 218 patients enrolled in the study. 66 patients (30%) had ovarian or fallopian tube cancer (97% epithelial), 124 (57%) had benign masses, 17 (8%) had borderline tumors, and 11 (5%) had metastatic disease. The SI, CA125 and HE4 were positive in 87.9%, 74.2% and 60.6% of ovarian cancer patients, respectively. Of the 112 women with a positive SI 58 (52%) had ovarian cancer and 75 (67%) had non-benign masses. Excluding borderline and metastatic cancers the sensitivity of the triple screen was 79%; specificity 91%, PPV 83% and NPV 89%. CA125 alone had a sensitivity, specificity, PPV and NPV of 79%, 76%, 63% and 87% respectively. Requiring only one of the three tests to be abnormal resulted in a sensitivity of 97% but specificity dropped to 50%. CONCLUSIONS: An algorithm using SI, CA125 and HE4 has good performance statistics for predicting cancer in women with pelvic masses. The triple screen has higher specificity and PPV than CA125 alone but similar sensitivity and NPV for predicting ovarian cancer.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/sangue
Antígeno Ca-125/sangue
Proteínas de Membrana/sangue
Neoplasias Ovarianas/sangue
Neoplasias Ovarianas/diagnóstico
Proteínas/metabolismo
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias das Tubas Uterinas/sangue
Neoplasias das Tubas Uterinas/diagnóstico
Feminino
Seres Humanos
Meia-Idade
Projetos Piloto
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CA-125 Antigen); 0 (MUC16 protein, human); 0 (Membrane Proteins); 0 (Proteins); 0 (WFDC2 protein, human)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE


  8 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28816970
[Au] Autor:Otsuka I; Matsuura T
[Ad] Endereço:Department of Gynecology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, Japan.
[Ti] Título:Skin metastases in epithelial ovarian and fallopian tube carcinoma.
[So] Source:Medicine (Baltimore);96(33):e7798, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study aimed to investigate the clinical features and outcomes of skin metastasis in ovarian and fallopian tube carcinomas.We studied patients with epithelial ovarian or fallopian tube carcinoma who developed skin metastasis from 2001 through 2012, and were also treated with chemotherapy and/or surgery.Skin metastases were classified as umbilical metastasis (Sister Joseph nodule [SJN]) and nonumbilical metastasis. Patients who developed skin metastases at paracentesis sites were excluded.Of the 206 patients treated, 12 (5.8%) developed skin metastasis: 7 developed SJN, and 5 developed nonumbilical metastasis. Six patients had serous carcinoma, 3 had clear cell carcinoma, 2 had endometrioid carcinoma, and 1 had adenocarcinoma. Four patients out of the 7 who developed SJN had skin metastasis at initial diagnosis, and all 4 patients had SJN with concomitant peritoneal dissemination. Of the 4 patients, 3 received chemotherapy, and their survival ranged from 22 to 42 months. Of the 7 patients who developed SJN, 3 patients with stage IIIC disease developed an SJN at recurrence and were treated with surgery and/or chemotherapy. Their survival duration after recurrence ranged from 26 to 43+ months. Five patients developed nonumbilical metastases 3 to 53 months (median 34 months) after initial diagnosis: 3 cases occurred in incisional scars of primary surgery, and 2 in subcutaneous metastasis in the other sites. Survival after recurrence ranged from 56 to 140+ months in 3 patients with incisional scar recurrence, and it was 5 months in 2 other patients.Sister Joseph nodule developed only in patients with peritoneal dissemination, and most patients with SJN survived for >24 months. Nonumbilical metastases occurring in incisional scars of primary surgery may carry a favorable prognosis.
[Mh] Termos MeSH primário: Neoplasias das Tubas Uterinas/patologia
Neoplasias Ovarianas/patologia
Neoplasias Cutâneas/secundário
[Mh] Termos MeSH secundário: Idoso
Neoplasias das Tubas Uterinas/mortalidade
Feminino
Seres Humanos
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Ovarianas/mortalidade
Neoplasias Cutâneas/mortalidade
Neoplasias Cutâneas/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007798


  9 / 2274 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802766
[Au] Autor:Thaker PH; Brady WE; Lankes HA; Odunsi K; Bradley WH; Moore KN; Muller CY; Anwer K; Schilder RJ; Alvarez RD; Fracasso PM
[Ad] Endereço:Division of Gynecologic Oncology, Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO, USA. Electronic address: thakerp@wudosis.wustl.edu.
[Ti] Título:A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
[So] Source:Gynecol Oncol;147(2):283-290, 2017 Nov.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The study's purpose was to assess safety and efficacy of escalating doses of weekly GEN-1 with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers (EOC). METHODS: Patients had persistent or recurrent platinum-resistant EOC. The trial was a standard 3+3 phase I dose escalation design with patients receiving intravenous PLD 40mg/m (dose level 1 and 2) or 50mg/m (dose level 3) every 28days and intraperitoneal GEN-1 at 24mg/m (dose level 1) or 36mg/m (dose level 2 and 3) on days 1, 8, 15, and 22 of a 28day cycle. Cycles were repeated every 28days until disease progression. Patients were monitored for toxicity, clinical efficacy, and evidence of systemic and intraperitoneal immunologic effect. RESULTS: Sixteen evaluable patients received a median of 4cycles (range 1-8). No dose limiting toxicities were found. The adverse side effects were 4 grade 3 anemia, 2 grade 3 abdominal pain, 7 grade 3 neutropenia, and 2 grade 4 neutropenia. A clinical benefit of 57.1% (PR=21.4%; SD=35.7%) was found in the 14 patients with measurable disease. The highest number of partial responses (28.6%) and stable disease (57.1%) were found at dose level 3. The maximum tolerated dose was not reached. Increases in IL-12, IFN-γ, and TNF-α levels were found in peritoneal fluid following GEN-1 treatment. CONCLUSIONS: GEN-1 in combination with PLD has encouraging clinical benefit and biological activity in recurrent or persistent EOC and warrants further investigation with escalating doses of GEN-1.
[Mh] Termos MeSH primário: Doxorrubicina/análogos & derivados
Neoplasias das Tubas Uterinas/terapia
Terapia Genética/métodos
Interleucina-12/genética
Neoplasias Epiteliais e Glandulares/terapia
Neoplasias Ovarianas/terapia
Neoplasias Peritoneais/terapia
[Mh] Termos MeSH secundário: Idoso
Antibióticos Antineoplásicos/administração & dosagem
Intervalo Livre de Doença
Relação Dose-Resposta a Droga
Doxorrubicina/administração & dosagem
Neoplasias das Tubas Uterinas/tratamento farmacológico
Neoplasias das Tubas Uterinas/genética
Feminino
Seres Humanos
Interleucina-12/administração & dosagem
Meia-Idade
Recidiva Local de Neoplasia/tratamento farmacológico
Recidiva Local de Neoplasia/genética
Neoplasias Epiteliais e Glandulares/tratamento farmacológico
Neoplasias Epiteliais e Glandulares/genética
Neoplasias Ovarianas/tratamento farmacológico
Neoplasias Ovarianas/genética
Neoplasias Peritoneais/tratamento farmacológico
Neoplasias Peritoneais/genética
Plasmídeos/administração & dosagem
Plasmídeos/genética
Polietilenoglicóis/administração & dosagem
Polietilenoimina/administração & dosagem
Polietilenoimina/análogos & derivados
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 0 (liposomal doxorubicin); 0 (poly(ethylene glycol)-co-poly(ethyleneimine)); 187348-17-0 (Interleukin-12); 30IQX730WE (Polyethylene Glycols); 80168379AG (Doxorubicin); 9002-98-6 (Polyethyleneimine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171118
[Lr] Data última revisão:
171118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  10 / 2274 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28756871
[Au] Autor:Cohn DE; Sill MW; Walker JL; O'Malley D; Nagel CI; Rutledge TL; Bradley W; Richardson DL; Moxley KM; Aghajanian C
[Ad] Endereço:Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States. Electronic address: David.Cohn@osumc.edu.
[Ti] Título:Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
[So] Source:Gynecol Oncol;146(3):477-483, 2017 Sep.
[Is] ISSN:1095-6859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. PATIENTS AND METHODS: Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80mg/m intravenously days 1, 8, and 15 every 4weeks) or the combination of paclitaxel (80mg/m intravenously days 1, 8, and 15) plus reovirus 3×10 TCID /day intravenously on days 1-5, both every 4weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%. RESULTS: The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3months for paclitaxel and 4.4months for paclitaxel plus reovirus (hazard ratio, 1.11; 90% two-sided CI, 0.78 to 1.59; one-sided P=0.687). The proportion responding (overall response rate) to paclitaxel was 20% among 45 patients with measurable disease receiving paclitaxel alone, and 17.4% among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90% CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade≥4, 12% versus 0%), and severe respiratory adverse events (grade≥3, 25% versus 2%). No deaths were considered treatment related. CONCLUSION: The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.
[Mh] Termos MeSH primário: Antineoplásicos Fitogênicos/uso terapêutico
Carcinoma/terapia
Neoplasias das Tubas Uterinas/terapia
Recidiva Local de Neoplasia/terapia
Neoplasias Epiteliais e Glandulares/terapia
Terapia Viral Oncolítica
Neoplasias Ovarianas/terapia
Paclitaxel/uso terapêutico
Neoplasias Peritoneais/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Terapia Combinada/efeitos adversos
Intervalo Livre de Doença
Feminino
Seres Humanos
Meia-Idade
Neutropenia/etiologia
Terapia Viral Oncolítica/efeitos adversos
Vírus Oncolíticos
Paclitaxel/efeitos adversos
Estudos Prospectivos
Reoviridae
Doenças Respiratórias/etiologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents, Phytogenic); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE



página 1 de 228 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde